Gene therapy is a promising field of biotechnology that aims to treat or cure diseases by introducing genetic material into cells. Gene therapy has the potential to address many unmet medical needs, such as inherited disorders, cancer, and infectious diseases. However, gene therapy also poses significant challenges and risks, such as immune reactions, off-target effects, and long-term consequences. Therefore, gene therapy requires rigorous safety evaluation before it can be applied to humans.
One of the most important tools for gene therapy safety evaluation is the use of non-human primates (NHPs), such as monkeys and apes. NHPs are closely related to humans in terms of genetics, physiology, immunology, and behavior. They can provide valuable information on the biodistribution, pharmacokinetics, efficacy, and toxicity of gene therapy products that cannot be obtained from other animal models or in vitro studies. NHPs can also help to predict the potential adverse events and outcomes of gene therapy in humans.
However, the use of NHPs in gene therapy safety evaluation also raises ethical, scientific, and regulatory issues. NHPs are highly sentient and social animals that deserve respect and protection. They are also scarce and expensive resources that should be used sparingly and efficiently. Moreover, they are subject to different regulations and guidelines in different countries and regions, which can affect the quality and comparability of the data generated from NHP studies.
Therefore, it is essential to follow best practices for using NHPs in gene therapy safety evaluation. In this blog post, we will discuss some of these best practices, such as:
- Selecting the most appropriate NHP species and strain for the gene therapy product and target disease
- Designing the NHP study with adequate sample size, duration, endpoints, and controls
- Conducting the NHP study in accordance with the principles of replacement, reduction, and refinement (3Rs) of animal use
- Applying rigorous standards for animal welfare and ethical review
- Reporting the NHP study results transparently and comprehensively
- Harmonizing the NHP study requirements and expectations across different regulatory authorities
Non-human primates have played a critical role in advancing gene therapy research, and several successful examples include:
1. Treatment of Hemophilia B: In a study published in the New England Journal of Medicine in 2011, researchers used gene therapy to treat Hemophilia B in rhesus macaques. The researchers used adeno-associated virus (AAV) to deliver the missing gene to the liver. The treatment corrected the bleeding defect in the primates, and the therapy was subsequently tested and approved for use in humans.
2. Treatment of Parkinson's disease: In a study published in the journal Nature in 2017, researchers used gene therapy to treat Parkinson's disease in primates. The researchers used a modified virus to deliver a new gene to the brain cells affected by Parkinson's disease. The gene encodes for a protein that helps produce dopamine, which is essential for controlling movement. The treated primates showed significant improvement in their motor function.
3. Treatment of Leber's congenital amaurosis: In a seminal study published in the New England Journal of Medicine in 2008, researchers used gene therapy to treat Leber's congenital amaurosis, a rare inherited form of blindness in children. The researchers used AAV to deliver the correct copy of the disease-causing gene to the affected cells of the retina. The treatment improved the retinal function in the treated non-human primates and subsequently in humans.
These studies demonstrate the usefulness of non-human primates in gene therapy research and provide an important step towards advancing human gene therapy.
By following these best practices, we can ensure that NHPs are used effectively and responsibly in gene therapy safety evaluation. This will not only benefit the development and approval of safe and effective gene therapy products for human patients but also contribute to the advancement of scientific knowledge and animal welfare.
